UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 448

Sortiert nach

Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase

Journal of medicinal chemistry, 2010-04, Vol.53 (8), p.3396-3411

2010

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo anti‐epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2‐related self‐limited epilepsy

British journal of pharmacology, 2022-01, Vol.179 (1), p.84-102

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double‐blind, randomized, parallel‐group, multicenter study

Epilepsia (Copenhagen), 2018-02, Vol.59 (2), p.479-491

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease

Movement disorders, 2022-11, Vol.37 (11), p.2272-2283

2022

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic‐Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS)

Journal of clinical pharmacology, 2020-05, Vol.60 (5), p.617-628

2020

Link zum Volltext

Verfügbarkeit prüfen

Development of Blood–Brain Barrier Permeable Nitrocatechol-Based Catechol O‑Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity

Journal of medicinal chemistry, 2016-08, Vol.59 (16), p.7584-7597

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers

Molecular nutrition & food research, 2009-05, Vol.53 (S1), p.S7-S15

2009

Link zum Volltext

Verfügbarkeit prüfen

Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

Epilepsia (Copenhagen), 2013-01, Vol.54 (1), p.108-116

2013

Link zum Volltext

Verfügbarkeit prüfen

Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474

British journal of pharmacology, 2020-05, Vol.177 (9), p.2123-2142

2020

Link zum Volltext

Verfügbarkeit prüfen

Inactivation Mechanism of the Fatty Acid Amide Hydrolase Inhibitor BIA 10‐2474

Chembiochem : a European journal of chemical biology, 2022-10, Vol.23 (20), p.e202200166-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Integrated analysis of pooled data from double‐blind phase III clinical studies

Epilepsia (Copenhagen), 2013-01, Vol.54 (1), p.98-107

2013

Link zum Volltext

Verfügbarkeit prüfen

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

Lancet neurology, 2016-02, Vol.15 (2), p.154-165

2016

Link zum Volltext

Verfügbarkeit prüfen

Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate

Acta neurologica Scandinavica, 2020-05, Vol.141 (5), p.397-404

2020

Link zum Volltext

Verfügbarkeit prüfen

Cellular and Mitochondrial Toxicity of Tolcapone, Entacapone, and New Nitrocatechol Derivatives

ACS pharmacology & translational science, 2024-05, Vol.7 (5), p.1637-1649

2024

Link zum Volltext

Verfügbarkeit prüfen

Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled‐release carbamazepine in noninferiority epilepsy monotherapy trials: How much “fair” is “fair”

Epilepsia (Copenhagen), 2018-04, Vol.59 (4), p.900-901

2018

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and drug interactions of eslicarbazepine acetate

Epilepsia (Copenhagen), 2012-06, Vol.53 (6), p.935-946

2012

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a Potent, Long‐Acting, and CNS‐Active Inhibitor (BIA 10‐2474) of Fatty Acid Amide Hydrolase

ChemMedChem, 2018-10, Vol.13 (20), p.2177-2188

2018

Link zum Volltext

Verfügbarkeit prüfen

Medicinal Chemistry of Catechol O‑Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility

Journal of medicinal chemistry, 2014-11, Vol.57 (21), p.8692-8717

2014

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique

Epilepsia (Copenhagen), 2012-03, Vol.53 (3), p.529-538

2012

Link zum Volltext

Verfügbarkeit prüfen

Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping

Pharmacology research & perspectives, 2022-02, Vol.10 (1), p.e00891-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review

Drugs (New York, N.Y.), 2019-04, Vol.79 (6), p.593-608

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study

Epilepsia (Copenhagen), 2009-03, Vol.50 (3), p.454-463

2009

Link zum Volltext

Verfügbarkeit prüfen

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial‐onset seizures: Results of a phase III, double‐blind, randomized, placebo‐controlled trial

Epilepsia (Copenhagen), 2015-02, Vol.56 (2), p.244-253

2015

Link zum Volltext

Verfügbarkeit prüfen

Optimization of a Parallel Artificial Membrane Permeability Assay for the Fast and Simultaneous Prediction of Human Intestinal Absorption and Plasma Protein Binding of Drug Candidates: Application to Dibenz[b,f]azepine-5-Carboxamide Derivatives

Journal of pharmaceutical sciences, 2012-02, Vol.101 (2), p.530-540

2012

Link zum Volltext

Verfügbarkeit prüfen

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action

Pharmacology research & perspectives, 2015-03, Vol.3 (2), p.e00124-n/a

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 448

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(433)
Mit Volltextzugriff
(408)

Publikationsform

Artikel
(442)
Buchkapitel
(6)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase

In vitro and in vivo anti‐epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2‐related self‐limited epilepsy

Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double‐blind, randomized, parallel‐group, multicenter study

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease

Population Pharmacokinetic‐Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS)

Development of Blood–Brain Barrier Permeable Nitrocatechol-Based Catechol O‑Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers

Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474

Inactivation Mechanism of the Fatty Acid Amide Hydrolase Inhibitor BIA 10‐2474

Efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Integrated analysis of pooled data from double‐blind phase III clinical studies

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate

Cellular and Mitochondrial Toxicity of Tolcapone, Entacapone, and New Nitrocatechol Derivatives

Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled‐release carbamazepine in noninferiority epilepsy monotherapy trials: How much “fair” is “fair”

Pharmacokinetics and drug interactions of eslicarbazepine acetate

Discovery of a Potent, Long‐Acting, and CNS‐Active Inhibitor (BIA 10‐2474) of Fatty Acid Amide Hydrolase

Medicinal Chemistry of Catechol O‑Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility

Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique

Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping

Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial‐onset seizures: Results of a phase III, double‐blind, randomized, placebo‐controlled trial

Optimization of a Parallel Artificial Membrane Permeability Assay for the Fast and Simultaneous Prediction of Human Intestinal Absorption and Plasma Protein Binding of Drug Candidates: Application to Dibenz[b,f]azepine-5-Carboxamide Derivatives

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action

Suchergebnisse filtern